Survodutide 6mg

Survodutide (6 mg) is a synthetic, long-acting peptide supplied as a lyophilized powder per vial for controlled laboratory and preclinical research. The Survodutide peptide belongs to a class of metabolic research compounds that are being investigated for systemic energy regulation and endocrine signaling.

Survodutide, classified under weight loss and metabolic peptides, is an investigational dual GLP-1 / glucagon receptor agonist derived from a modified 29–amino acid glucagon backbone. It is engineered to support extended activity in experimental models, including once-weekly administration paradigms used in research protocols.

• Chemical Formula: C₁₉₂H₂₈₉N₄₇O₆₁
• Molecular Weight: 4231.63 g/mol
• Peptide Sequence: His-{1-Aminocyclobutanecarboxylic acid}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-{Lys(Gly-Ser-Gly-Ser-Gly-Gly-γGlu-C18 diacid)}-Trp-Leu-Glu-Ser-Ala-NH2

Also known as BI 456906 (CAS Number: 2805997-46-8), Survodutide incorporates C18 fatty diacid conjugation attached via a hydrophilic linker to a specific lysine residue. This structural design promotes reversible albumin binding, as shown in studies to prolong circulation time and reduce enzymatic degradation.

Research-grade Survodutide is typically produced with high analytical purity (≥98%), and its molecular identity is confirmed by mass spectrometry. In published clinical and translational research, it has been evaluated for effects on body-weight regulation, hepatic lipid metabolism, glycemic parameters, and metabolic dysfunction–associated steatohepatitis (MASH).

The 6 mg vial format reflects the upper dose evaluated in Phase 2 dose-escalation studies and supports comparative dose-response research and protocol modeling in laboratory environments. Qualified laboratories that buy Survodutide peptide should source it through authorized research suppliers and follow all applicable institutional requirements.

• Defined peptide composition: Synthetic 29–amino acid glucagon-derived peptide with dual GLP-1 and glucagon receptor activity
• High-purity standard: Manufactured at ≥98% purity, verified by HPLC and mass spectrometry
• 6 mg lyophilized vial: Suitable for dose-escalation studies and preparation of multiple research solutions
• Extended-activity design: C18 fatty diacid conjugation supports albumin binding and prolonged exposure in experimental models
• Metabolic research focus: Investigated in obesity, MASH, glycemic control, and energy-expenditure research
• Stable dry formulation: Lyophilized presentation supports long-term frozen storage
• Research-supply suitability: Appropriate for laboratories that order Survodutide peptide for metabolic research
• For laboratory research use only: Not intended for diagnostic, therapeutic, or clinical applications in humans or animals

Survodutide is researched as a dual-acting metabolic peptide that combines incretin-like signaling with glucagon-mediated effects. Experimental studies examine how concurrent activation of these pathways influences appetite regulation, energy balance, and hepatic lipid handling.

This dual-pathway profile differentiates Survodutide from single-receptor incretin analogs and has been central to its investigation in metabolic research.

Reported research applications include:

• Body-weight regulation: Studied in adults with obesity to assess changes in body weight and adiposity
• Metabolic liver disease: Investigated in MASH to evaluate changes in liver fat content and histologic disease activity
• Hepatic lipid metabolism: Examined for effects on lipid utilization and turnover
• Glycemic parameters: Studied for changes in HbA1c and glucose regulation in metabolic disease models
• Energy expenditure: Evaluated for effects on systemic energy balance through combined incretin and glucagon activity

All applications described are investigational and have been evaluated exclusively within regulated clinical or preclinical research settings.

The following information summarizes dosing levels and observations reported in published studies. It is provided solely for research context and does not constitute dosing recommendations.

Phase 2 clinical studies evaluated once-weekly subcutaneous dosing at 2.4 mg, 4.8 mg, and 6.0 mg following gradual dose escalation.

• In obesity studies, the 4.8 mg dose demonstrated the most favorable balance of study endpoints, with mean body-weight reductions approaching 15% over 48 weeks. Escalation to 6.0 mg did not improve weight-related outcomes and was associated with higher rates of adverse events.
• In MASH studies, dose-dependent effects were reported for liver-fat reduction and disease-activity improvement. Rates of MASH improvement without fibrosis worsening were 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg), compared with 14% for placebo.
• Fibrosis improvement of at least one stage was modest across all active doses and did not show a clear dose-response pattern.
• Glycemic measures, including HbA1c, were evaluated in participants with metabolic disease and generally aligned with doses that performed best on weight and liver fat endpoints.

The 6 mg vial format supports comparative dose-response analysis and protocol modeling in laboratory research.

• Lyophilized (unopened):
  • Store at –20 °C or colder for long-term stability
  • Protect from moisture and direct light
  • Brief room temperature exposure is acceptable during transport
• After reconstitution:
  • Store at 2–8 °C, protected from light
  • Stability is generally 2–4 weeks, depending on solution composition and handling
• Avoid repeated freeze–thaw cycles, which may compromise peptide integrity
• Discard solutions showing particulates or discoloration

As an investigational bioactive peptide, Survodutide should be handled in accordance with standard laboratory safety procedures. Personnel should avoid inhalation, ingestion, skin contact, or accidental injection, and wear appropriate personal protective equipment. Disposal of unused material must follow applicable institutional, local, and regulatory guidelines.

References

https://pubmed.ncbi.nlm.nih.gov/38330987/

https://pubmed.ncbi.nlm.nih.gov/38847460/

https://pubmed.ncbi.nlm.nih.gov/36356832/

https://pubmed.ncbi.nlm.nih.gov/38560764/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.